title: Current treatment options for invasive aspergillosis.
abstract: Invasive pulmonary aspergillosis is a major cause of morbidity and mortality in immunocompromised patients, particularly those with hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplant recipients. The optimal therapy for invasive aspergillosis relies on the restoration of leukocyte counts and effective antifungal treatment initiated at the earliest stage of infection. Several alternative antifungal compounds are currently available. A rational approach should take into account not only the degree of certainty of infection (as codified by the EORTC/MSG classification), but also previous exposure to other antifungals, the pharmacokinetic and pharmacodynamic characteristics of the antifungals employed and the clinical characteristics of the patient.
authors.affiliation: Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, São Paulo, Brazil. marjorie.mi@gmail.com
authors.forename: M V
authors.initials: MV
authors.lastname: Batista
authors.forename: S F
authors.initials: SF
authors.lastname: Costa
authors.forename: M A
authors.initials: MA
authors.lastname: Shikanai-Yasuda
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy* / Q000517:prevention & control; D007958:Leukocyte Count; D009894:Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology; D013997:Time Factors
chemical_list: D000935:Antifungal Agents
keywords: Amphotericin B; Antifungal drugs; Antifungal therapy; Azoles; Caspofungin; Echinocandins; Immunocompromised hosts; Invasive aspergillosis; Invasive fungal infection; Polyene antibiotics; Voriconazole